<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Treatment with <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (TZDs) produces <z:mp ids='MP_0005456'>weight gain</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To test whether a portion control diet could prevent <z:mp ids='MP_0005456'>weight gain</z:mp> during treatment with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN: This 16-week randomized, open-label, parallel arm study compared three groups: (i) <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> plus the American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association diet (Pio + <z:chebi fb="36" ids="39048">ADA</z:chebi>); (ii) <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> plus a portion control <z:hpo ids='HP_0001824'>weight loss</z:hpo> diet (Pio + PC); (iii) <z:chebi fb="0" ids="6801">metformin</z:chebi> plus the American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association diet (Met + <z:chebi fb="36" ids="39048">ADA</z:chebi>) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> participants received the same advice about calorie reduction, lifestyle change and exercise </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Fifty-one men and women with T2DM, naive to TZDs, were randomized to a 16-week study </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> (Pio) was titrated to a dose of 45 mg/day and <z:chebi fb="0" ids="6801">metformin</z:chebi> (Met) to a dose of 2 g/day </plain></SENT>
<SENT sid="6" pm="."><plain>Fasting blood was collected for <z:chebi fb="23" ids="18059">lipids</z:chebi>, insulin and glycosylated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> A1c (HbA1c) at baseline and 16 weeks </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Forty-eight of fifty-one randomized subjects completed the study </plain></SENT>
<SENT sid="8" pm="."><plain>Patients treated with Pio + <z:chebi fb="36" ids="39048">ADA</z:chebi> gained 2.15 +/- 1.09 kg (mean +/- SD) compared with a <z:hpo ids='HP_0001824'>weight loss</z:hpo> of 2.59 +/- 1.25 kg (p &lt; 0.05) in the Pio + PC group, and a <z:hpo ids='HP_0001824'>weight loss</z:hpo> of 3.21 +/- 0.7 kg (p &lt; 0.05) in the Met + <z:chebi fb="36" ids="39048">ADA</z:chebi> group </plain></SENT>
<SENT sid="9" pm="."><plain>Waist circumference and visceral adipose tissue decreased significantly more in the Pio + PC group than in the Pio + <z:chebi fb="36" ids="39048">ADA</z:chebi> group </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="1" ids="47775">High-density lipoprotein cholesterol</z:chebi> levels were significantly increased in the Pio + PC group compared with the Met + <z:chebi fb="36" ids="39048">ADA</z:chebi> group </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> reduced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (homeostasis model assessment of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (HOMA-IR)) more than <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>No significant differences between groups were seen for <z:chebi fb="105" ids="17234">glucose</z:chebi>, insulin, HbA1c or <z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi> levels </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Pio + PC, prevented <z:mp ids='MP_0005456'>weight gain</z:mp>, reduced waist circumference and visceral fat compared with Pio + <z:chebi fb="36" ids="39048">ADA</z:chebi> diet </plain></SENT>
</text></document>